A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and Treatment Utilizing Shenling Baizhu Powder

被引:7
|
作者
Meng, Meng [1 ]
Bai, Chen [2 ]
Wan, Bo [3 ]
Zhao, Luqing [1 ]
Li, Zhe [1 ]
Li, Danyan [1 ]
Zhang, Shengsheng [1 ]
机构
[1] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Digest Ctr, Beijing, Peoples R China
[2] Beijing Univ Chinese Med, Beijing, Peoples R China
[3] Kings Coll London, Guys Hosp, Ctr Stem Cells & Regenerat Med, London, England
关键词
GASTROENTEROLOGY MONOGRAPH; AMERICAN-COLLEGE; MANAGEMENT; CANCER; IBD;
D O I
10.1155/2021/4579850
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background and Objective. Irritable bowel syndrome (IBS) is a prevalent disorder of the gastrointestinal system with complex pathogenesis. Shenling Baizhu powder (SLBZP) is a Chinese herbal compound with multicomponent and multitarget characteristics. Increasing volumes of evidence demonstrate that it has a notable therapeutic impact on IBS. This study therefore is aimed at exploring the potential effective components of SLBZP and their mechanisms in IBS treatment utilizing network pharmacology. Methods. Metabolomics was used to detect the secondary metabolites in SLBZP; the target protein was acquired by target fishing according to the compound's structure. The SymMap database was used to search herbal medicines for the target protein. The target gene of IBS gave rise to the common gene protein which is the potential target of SLBZP in IBS therapy. The interactions between target proteins were analyzed in a STRING database, the protein relationship network was analyzed using Cytoscape software, and the Kyoto Encyclopedia of Genes and Genomes enrichment analysis of the core target gene group was carried out in a DAVID database in order to construct the "compound-traditional Chinese medicine/ molecule-target-pathway" network. Molecular docking was used to verify the core protein and its related small molecular compounds. Result. There were 129 types of secondary metabolites in SLBZP. 80 target proteins of these metabolites were potential core targets for IBS treatment including acetylcholinesterase (AChE), arachidonate-5-lipoxygenase (ALOX5), B-cell lymphoma-2 (BCL2), recombinant cyclin D1 (CCND1), and catenin-beta 1 (CTNNB1), among others. Results from these targets indicated that the most enriched pathway was the tumor necrosis factor (TNF) signaling pathway (p < 0:001) and that the most abundant pathway was signal transduction. In the network nodes of the TNF signaling pathway, the Chinese medicines with the highest aggregation were Lablab semen album and Glycyrrhizae radix et rhizoma (degree = 11). The small molecules with the highest aggregation were oxypeucedanin and 3,5,6,7,8,3',4'- heptamethoxyflavone (degree = 4). Molecular docking results confirmed that daidzein 7-O-glucoside (daidzin) had the highest degree of binding to TNF proteins in the TNF signaling pathway. Conclusion. This study shows that SLBZP can treat IBS by influencing multiple targets and pathways, of which the TNF signaling pathway may be the most significant. This typifies the pharmacological characteristics of traditional Chinese medicine, i.e., multiple targets, numerous pathways, and specific therapeutic effects on diseases. SLBZP can therefore be used as a candidate drug for clinical IBS by intervening in human signal transduction.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Network pharmacology-based study to explore the mechanism of the Yiqi Gubiao pill in lung cancer treatment
    Li, Zheng
    Xu, Dan
    Jing, Jing
    Li, Fengsen
    ONCOLOGY LETTERS, 2021, 21 (04)
  • [32] Naloxone treatment for irritable bowel syndrome - A pilot study
    Hawkes, ND
    Rhodes, J
    Evans, B
    Hawthorne, B
    Thomas, G
    GASTROENTEROLOGY, 2002, 122 (04) : A552 - A553
  • [33] Pharmacology and metabolism of renzapride - A novel therapeutic agent for the potential treatment of irritable bowel syndrome
    Meyers, Nicholas L.
    Hickling, Roger I.
    DRUGS IN R&D, 2008, 9 (01) : 37 - 63
  • [34] Pharmacology and Metabolism of RenzaprideA Novel Therapeutic Agent for the Potential Treatment of Irritable Bowel Syndrome
    Nicholas L. Meyers
    Roger I. Hickling
    Drugs in R&D, 2008, 9 : 37 - 63
  • [35] Network Pharmacology-Based Study on the Efficacy and Mechanism of Lonicera japonica Thunberg
    Park, Sang Jun
    Kim, Mi Hye
    Yang, Woong Mo
    APPLIED SCIENCES-BASEL, 2022, 12 (18):
  • [36] Network Pharmacology-Based Study on the Mechanism of Aloe Vera for Treating Cancer
    Xie, Jing
    Wu, Jun
    Yang, Sihui
    Zhou, Huaijun
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [37] Network Pharmacology-Based Investigation of the Mechanism of Action of Plantaginis Herba in Hyperuricemia Treatment
    Tang, Rong
    Peng, Xiaoqing
    Wang, Yan
    Zhou, Xiaohong
    Liu, Hong
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [38] Network Pharmacology-Based Validation of the Efficacy of Huiyangjiuji Decoction in the Treatment of Experimental Colitis
    Yu, Wei
    Cheng, Hongju
    Zhu, Baoliang
    Yan, Jing
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [39] Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis
    Yu, Guohua
    Wang, Wubin
    Wang, Xu
    Xu, Meng
    Zhang, Lili
    Ding, Lei
    Guo, Rui
    Shi, Yuanyuan
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 18
  • [40] Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19
    Zeng, Yijia
    Lou, Guanhua
    Ren, Yuanyuan
    Li, Tingna
    Zhang, Xiaorui
    Wang, Jin
    Huang, Qinwan
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2021, 42